




FIG. 1




FIG. 2





FIG. 3



Non-validated output
Symbols represent censored observations
Active arms include 25 mg QD, 25 mg BID, 50 mg BID, 100 mg BID

FIG. 4




FIG. 5





FIG. 6






FIG. 8




FIG. 9A




FIG. 9B





FIG. 9C



Treatment G: 200 mg milvexian (2x 100 mg film-coated DC oral tablet) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)
Treatment H: 200 mg milvexian (2x 100 mg Phase 2 oral capsules: BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

FIG. 10A






FIG. 10B



Treatment I: 25 mg milvexian (1x 25 mg film-coated DC oral tablet BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)
Treatment J: 25 mg milvexian (1x 25 mg Phase 2 oral capsule) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

FIG. 10C



Treatment I: 25 mg milvexian (1x 25 mg film-coated DC oral tablet BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)
Treatment J: 25 mg milvexian (1x 25 mg Phase 2 oral capsule) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

FIG. 10D




FIG. 11